A B S T R A C T Patients with acute leukemia were given repeated cycles consisting of infusions of methotrexate followed by "rescue" with folinic acid. Peripheral blood leukemic cells were harvested from patients before cyclical treatment, and the rates of incorporation of thymidine and of deoxyuridine into deoxyribonucleic acid (DNA) were measuared in vitro. There was no relationship between the pretreatment incorporation of either deoxynucleoside into DNA and the clinical response to therapy. Methotrexate suppressed deoxyuridine incorporation into DNA by the leukemic blasts in vitro, but the patients whose cells were most sensitive to this effect did not necessarily go into remission when treated.
Leukemic cells were sampled during methotrexate infusions and the deoxynucleoside incorporation rates were determined. Thymidine incorporation into DNA was variably affected. If, by the end of the first infusion, it remained elevated, remission rarely followed, whereas if it was below the pretreatment value, remission was much more likely. In all cases, deoxyuridine incorporation was suppressed during the infusion. The greatest suppression occurred in patients who went on to remission, but the suppression did not correlate with that expected from pretreatment in vitro tests unless due weight was given to the concomitant effects of the methotrexate therapy on thymidine incorporation. Leukemic 
INTRODUCTION
During the chemotherapy of malignant disease, some drugs produce much greater benefit if given in large infrequent doses instead of in small frequent doses. After the two modes of therapy, this can amount to the difference between complete eradication of the tumor versus no appreciable antitumor effect. Most notable in this respect is the folate antagonist, methotrexate (MTX) (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) . Evidently, some property of rapidly proliferating tumor cells renders them peculiarly susceptible to the lethal effects of large doses of MTX. In addition, the antidote to MTX, which is folinic acid or leucovorin, can in some circumstances rescue the host but not the tumor from MTX (7, (11) (12) (13) .
We have given patients with acute leukemia infusions of large doses of MTX followed immediately by folinic acid "rescue" and have studied the biochemical responses to MTX of the (deoxyribonucleic acid) DNA-synthesizing leukemic cells in the blood both before and during therapy. By correlating the biochemical responses of these cells with the outcome of therapy, we are attempting to detect those properties of malignant cells which are associated with the greatest vulnerability to large doses of the antifolate. This may point the way to therapeutic maneuvers which would further improve therapy results with MTX and may also contribute to a better understanding of the mechanism of action of antimetabolites in general.
MTX is well suited for this type of study, since it is not significantly metabolized in humans (14) , can be easily measured (15) , and its action is fairly well understood (16) . From Fig. 1 , it can be seen that the conversion of deoxyuridylate (dUMP) to thymidylate (dTMP) requires methylene tetrahydrofolate (hFH4) and that repletion of the pool of this folate is effected by dihydrofolate reductase (DHFR). MTX inhibits this enzyme, thus inhibiting synthesis of DNA since dUMP can no longer be methylated to dTMP (17, 18) . This blockade is believed to be responsible for the cytotoxic effects of MTX (17, 19) .
Since cells can phosphorylate exogenous deoxyuridine (UdR) to dUMP and thymidine (TdR) to dTMP, both deoxynucleosides can join the main pathway via the salvage pathway. Hence, the incorporation of UdR and TdR into DNA may serve as an index of the rate of DNA-synthesis. If dUMP conversion to dTMP were blocked, this would appear as inhibition of incorporation of tritiated UdR (UdR-5H) into DNA, but according to Fig. 1 , tritiated TdR (TdR-'H) should still be incorporated if the DNA-synthesizing system were otherwise unchanged by MTX. Normal or even enhanced incorporation of TdR-3H into DNA might occur (20 (21) . Erlenmeyer flasks were prepared, one series for each condition to be investigated. 1 ml aliquots of cell suspension were added to each flask equilibrated with 5% C0. The flasks were stoppered and set into a shaking metabolic incubator at 370C. Later, deoxynucleoside was added to each flask, either 9 X 10-' /moles UdR-8H, or 6 X 10-4 Mmoles TdR-8H. At intervals over the 3045 min after addition of deoxynucleoside ice-cold 5% perchloric acid (PCA) was added to a flask from each series. The precipitates that formed were washed free of acid-soluble radioactive compounds with 5% PCA, then hydrolyzed with 0.5 ml 5%
PCA by heating at 850C for 15 min. The radioactivity extracted from each precipitate was measured in a scintillation spectrometer with correction for efficiency of counting by external standardization. Counts were converted to a specific activity of 1.3 and 2.0 mc//Amole for UdR-8H and TdR-3H, respectively.
The radioactivity thus measured in each sample was plotted against the time of incubation. A linear relationship was usually obtained from each series of flasks for the 1st hr of incubation. The slope of this line was calculated (32) and represented the rate of incorporation of deoxynucleoside into DNA. Results were expressed as counts per minute of incubation per million blasts in the suspension. The standard deviation of the slope was calculated (32), and rates not significantly different from zero (33) were not used in subsequent calculations.
Incubation conditions. (a) Rates in the absence of MTX. Each series of cells in suspension was preincubated without added antifolate and then deoxynucleoside was added and the incorporation rate measured and expressed as described above. In addition, this "rate/106 blasts" was multiplied by the number of blasts, in millions, per milliliter of the original blood sample from which the cell suspension had been prepared and the rate thus calculated was termed "rate/milliliter of blood."' The cells harvested from patients during MTX infusions were preincubated for 10 min, while the cells serving as controls for the in vitro sensitivity studies were preincubated for 30 min before deoxynucleoside was added.
(b) Rates in the presence of MTX in vitro. Cells in suspension were preincubated with MTX at various concentrations (one series of flasks for each concentration) for 30 min at 370C, then deoxyuridine was added, and the rate of its incorporation into DNA measured as the rate/106 blasts. This rate was divided by the control rate (see above), and the resulting quotient, expressed as a decimal fraction, was called the "fractional UdR incorporation rate." A fractional UdR incorporation rate was thus derived for each concentration of MTX tested. The fractional UdR rates were plotted against their respective MTX concentrations on double-log paper ( Fig. 2) to give a dose-response relationship. No measurements were made of TdR rates after exposure to MTX in vitro.
Reproducibility of TdR and UdR rates. Adjustments in cell concentration in the suspension and number of samples in each series allowed accurate measurements to be made of low incorporation rates. By thus keeping the error proportional to the absolute value of the rate, plotting the results on a logarithmic scale was justified (34) . It was ascertained that 95-98% of the acid-insoluble counts (either from UdR or TdR) were in the DNA fraction. The counts remaining 'Example: If the "rate/106 blasts" were 100 cpm/min and the original blood sample had contained 10,000 blasts/mm' (10,000,000 blasts/ml), then the "rate/milliliter blood" would have been 100 X 10 = 1000 cpm/min. Patients had no previous exposure to MTX-folinic therapy.
in the RNA fraction could be accounted for by contaminating DNA. Several potential sources of variation were checked and, as shown in Table II , results of rate determinations of the rate/106 blasts in the absence of MTX were quite reproducible on any one day. Since the results of these tests were the same for both UdR and TdR, they are not distinguished in the table. These rates varied linearly with the concentration of blasts in the suspension up to 12 X 106/ml, and the line relating incorporation rate to blast number went through the origin. This indicated that cells present in the suspension other than blasts did not incorporate label. Incubations lasting over 1 hr frequently resulted in decreasing rates of label incorporation, and, therefore, total incubation time was kept to less than 1 hr. Fig. 2 shows the fractional UdR rates in the presence of MTX in vitro of the leukemic cells of one patient as repeatedly determined in the week preceding institution of MTX therapy. Test results were quite reproducible since all fractional UdR rates fell within the 95%o confidence limits of the dose-response line derived in the 1st day. In 24 of 25 such tests in 10 patients, the MTX sensitivity did not fluctuate significantly before therapy. The presence or absence of red cells did not appear to influence the sensitivity of blasts to MTX.
Rates measured during MTX therapy. Blood samples were drawn at approximately the 4th, 12th, and 24th hr of MTX infusion and the 4th and 24th hr of folinic acid therapy. Cell suspensions were prepared as described above, and UdR and TdR incorporation rates were measured after only a 10 min preincubation period at 370C (without MTX in the medium). The short preincubation period was chosen in an attempt to minimize efflux of intracellular drug.
Deoxynucleoside incorporation was thus measured during the drug infusions, and the rates were expressed both as per 10' blasts in suspension and per milliliter of blood as explained above. These rates were expressed as decimal fractions of the respective preinfusion values. Fig. 2 . This fractional UdR rate was compared with that actually determined on the blasts from the blood sample. As will become apparent, there was frequently a great discrepancy between the predicted and the observed fractional UdR rates derived in this way. We therefore calculated a correction factor which, when applied to the observed fractional UdR rate, produced good agreement between the predicted and the observed fractional UdR rates. 
CALCULATION OF CORRECTION FACTOR
The TdR incorporation rates measured during MTX infusions frequently were much different than the pretreatment (control) TdR rate in each infusion studied. We reasoned that the UdR rate corresponding to each of these TdR rates would likewise have risen or fallen to an equal degree were it not for the superimposed effect of MTX blocking conversion of dUMP to dTMP. Therefore, for each TdR rate during therapy, we calculated a corresponding UdR rate by increasing or decreasing the pretreatment control UdR rate to the same extent as each TdR rate was altered. This calculated UdR rate we took as the "control" suitable for each observed UdR rate. Then each observed UdR rate was divided by its corresponding calculated "control" and the resulting quotient, expressed as a decimal fraction, was the corrected fractional UdR rate observed during therapy.' 'Example: If the pretreatment TdR and UdR rates were 250 and 100 respectively but at the end of the MTX infusion were found to be 1000 and 2, then the TdR rate was (1000)/(250) or four times its control rate and the control UdR rate at this time would not have been 100, but would have been closer to (1000)/(250) X 100 or 400. Thus, a UdR
RESULTS

Clinical results
Remission rate. Five complete and seven partial remissions followed 25 courses of treatment in 21 patients (Table I) Rapid and profound changes occurred in peripheral blast counts during treatment. Fig. 3 
Effect of infusions of MTX on UdR incorporation.
The effect of MTX infusions on the rate of UdR incorporation by blasts is shown in Fig. 6 . Note that patients are subdivided according to which cycle of therapy was being studied. Overall, blast cells from responsive patients showed the greatest decreases of UdR incorporation. Those of nonresponsive patients studied during the 1st infusion showed less inhibition, and the inhibition was least in the blasts of nonresponsive patients studied during the 2nd and 3rd treatment cycles. The responses of each group are significantly different (P < 0.05) from each other at the 12th hr of the MTX infusion. At all time points, the inhibition produced in cells of responsive patients was significantly greater than that in nonresponsive patients studied during the 2nd or 3rd infusions. In responsive patients, blasts disappeared so quickly after the 1st MTX infusion that they could not be studied thereafter.
Effect of infusions of MTX on TdR incorporation. (Fig. 7 C) , and seven of these went on to remission. On the other hand, of the nine cases in which the TdR rate/milliliter blood had not decreased below pretreatment values by the 24th hr of MTX infusion, only one went on to remission (Fig. 7 D) . All the data shown in Fig. 7 pertain to studies of the 1st infusion of 1ITX in each patient. Correlation between in vitro and in vivo effects of MTX on UdR incorporation. As explained in the Methods section, fractional UdR rates were predicted for each MTX concentration measured during the infusions, and the fractional UdR rates actually observed were compared with this value. In both, the changes in the UdR rates were expressed as logs of decrease from pretreatment values. Fig. 8 A shows that there was a poor correlation between predicted and observed rates for the 1st log of blockade, i.e., for fractional rates from 1 to 0.1. This discrepancy can be best appreciated by noting that some UdR rates were observed to be even greater than the preinfusion rate despite the presence of MTX, giving rise to fractional rates greater than 1. In If the UdR rates observed during infusions were expressed as fractions of a corrected pretreatment UdR rate (see Methods, "calculation of correction factor"), then there was a good correlation between predicted and observed fractional UdR rates for the 1st log of blockade (Fig. 8 B) . However, the correlation between predicted and observed blockade at the 2nd and 3rd logs of blockade (fractional rates of 0.1-0.001) was the same (r = 0.65) regardless of whether or not the correction factor was applied and was significant (P < 0.05). The regression line relating the predicted with the corrected observed blockade had a slope of 1.10 ±0.07 (b ±Sb), indicating there was no systematic error in predicting blockade (slope not significantly different from 1). Fig. 9 shows three examples of studies correlating observed with predicted UdR rates during drug infu- 0.01O 0 sions, using appropriate correction factors derived from the concomitantly measured TdR rates (not shown). When this correction was applied to the fractional UdR rates shown in Fig. 6 , the differences between the rates of the patient groups narrowed, but patients studied during their 1st MTX infusion still showed significant differences from nonresponsive patients studied during their 2nd or 3rd MTX infusion.
When the corrections were applied to the pretreatment UdR rates to generate new "control" UdR rates, it was assumed that the pretreatment ratio of TdR to UdR incorporation rates would remain constant were it not for the presence of MTX. It would be therefore important to show that the ratio of TdR to UdR incorporation actually did remain stable if unperturbed by therapy. The ratio of TdR to UdR rate was 3.2 ±0.2 (SE) for both lymphoblastic and AGL and AMnL cells and was constant for a given patient despite changes in the dayto-day values of both rates. The correlation coefficient between the two rates was 0.99 for lymphoblastic cells and 0.98 for AGL and AMnL cells. Changes in resistance of cells to MTX in vitro. When cells were tested for sensitivity to MTX in vitro during therapy, changes occurred. In the patients whose disease subsequently remitted (Fig. 10) , the fractional UdR incorporation rate at 10' M MTX in vitro measured in cells harvested during the folinic acid infusions was increased above the pretreatment value but appeared to be returning toward base line levels thereafter. Blast counts declined so rapidly after the first cycle of therapy in this group that it was impossible to perform serial studies in all patients. In one case, complete remission occurred with only one infusion of MTX and folinic acid, even though the cells tested during the folinic infusion showed a fractional UdR rate 25-fold higher than the pretreatment cells. When the patient relapsed 50 days later, the cells had regained the original pretreatment fractional UdR rate and again the patient remitted on MTX-folinic therapy.
In patients in whom no remission occurred ( successive infusions of MTX and folinic acid showed a progressive rise in the fractional UdR rate at 10' M MTX in vitro, and these high fractional UdR rates were slow to return to pretreatment levels compared with the responsive cases. Thus, when therapy finally had to be abandoned in the nonresponsive group (indicated in Fig. 11 by the X's), the fractional UdR rates were uniformly higher (0.26-0.5) than the last tests available in the responsive group (0.1-0.15). Two patients had been treated 100 and 180 days before these biochemical studies were being done, and both had failed to respond. When tested for the first time, their blasts still showed fractional UdR rates of 10-M MTX which were higher than the patients tested before any treatment was given (compare with Fig. 5 ).
(g) Changes in DHFR enzyme activity. The changes in DHFR enzyme activity measured in relation to therapy are summarized in Table IV . Enzyme activity may be measured by performing the assay at pH 8.5 because the MTX-enzyme complex dissociates, but the value thus obtained probably does not represent the level of free intracellular enzyme. Rather, enzyme activity measured at the lower pH of 7.0 probably more closely approximates the level of free enzyme activity present in the intact cell (35) .
In patients with the most favorable responses, enzyme activity measured at pH 7.0 could not be detected during MTX infusions while that at pH 8.5 was reduced or unchanged (Table IVA) . In patients with partial remissions, activity at pH 7.0 was also undetectable but activity at pH 8.5 rose slightly near the end of the infusion. (Table IV B) . When the enzyme levels could be detected in the cells of patients who did not obtain a remission, the activity at pH 7.0 was not completely inhibited and even rose in some patients; enzyme activity at pH 8.5 was regularly increased by the end of the infusion (Table IV C) . DISCUSSION 
Clinical results
Patients who had lymphoblastic leukemia and who had not previously been treated with MTX obtained the best clinical responses, and the results compared favorably with other modes of therapy of leukemia relapsing after initial remission (36, 37) .
Gastrointestinal toxicity was not a major problem, but rnyelosuppression was more severe than was anticipated from a similar schedule in nonleukemic individuals (7) . This may have been due to a reduced granulocyte reserve pool and an increased MTX sensitivity of the normal elements in the leukemic marrow compared with the normal elements in the marrows of patients with carcinoma (38) . In addition, after patients with leukemia went into remission they experienced less myelotoxicity on the same high dose MTX schedule.
One of the most striking results of therapy was the rapid fall of the peripheral blast count. (Fig. 3) . The logarithm of the count frequently decreased linearly with time, implying exponential or random disappearance of cells. This rapid decline is difficult to explain if it is assumed that MTX affects only the proliferating fraction of the circulating blasts. This is because most circulating blasts are in a nonproliferative G, or Go phase (39, 40) and therefore should not be susceptible to the effects of MTX (17) . Therapy may have inhibited DNA synthesis in anatomical sites which had more proliferative potential than the blood, e.g. marrow and which maintained the input of blasts to the vascular compartment. Hence, the rapid fall of circulating blasts could be explained by inhibition of entry of blasts into the circulation from these sites rather than direct "kill" of circulating blasts. If so, then in the untreated patient there would be a significant "death rate" and rapid turnover of peripheral blasts, and the synthesis of new cells required to maintain the steady-state peripheral blast count could approximate 35 X 10' cells/24 hr (20 kg child with 10,000 blasts/ mm3 blood). Another explanation for the marked changes in the blast count in the peripheral blood might be that AMTX produces a direct lethal effect on blasts regardless of their place in the mitotic cycle. Some evidence exists that this may occur with high doses of MTX in experimental systems (41) .
Biochemical results
The test system. Attempts at predicting chemotherapeutic results based on drug effects on cells in vitro have been numerous (42) (43) (44) (45) (46) (47) (48) (49) (50) (51) (52) but none have achieved practical application. Several prerequisites for success of such attempts may be suggested. The mode of drug action must be known so that the in vitro test can monitor biochemical disturbances closely related to the drugs' cytostatic and cytocidal effects. In the present study, we chose to monitor the effects of MTX on DNA synthesis at the step of dUMP conversion to dTMP (Fig. 1 cytocidal effects primarily by blocking this step (17, 19 Potential sources of error in the test system considered were: varying rates of phosphorylation of deoxynucleosides, cleavage of deoxyribose from the pyrimidine bases, and exchange of ribose for deoxyribose (54) .
Error from these was judged minimal because incorporation was linear, rate determinations were replicable, and the ratio of TdR to UdR incorporation rate remained constant (Table II) . The sensitivity of blast cells to MTX in vitro before institution of treatment appeared stable as judged by the reproducibility of the fractional UdR rates. Serial pretreatment studies were not performed in patients whose blast counts were rapidly changing without therapy. Perhaps in such cases, the sensitivity of the blasts to MTX in vitro might not be as constant as those reported here. Also, comparisons of sensitivity of blasts in blood and marrow were not made and hence the relationship between the responses of peripheral and marrow blasts was not established. However, the system of study described here is easily adaptable to the blasts of the marrow, and investigations are currently underway to determine the effects of therapy on this potentially more important compartment of the leukemic cell population.
Clinical-biochemical Correlates
Pretreatment deoxynucleoside incorporation rates. It is believed that the larger the growth fraction of a population, the faster is the growth rate of that population, and the more susceptible is it to the lethal effects of antimetabolites (55) . One would expect that the deoxynucleoside incorporation rates/106 blasts would be some measure of the relative sizes of the growth fractions of different leukemic cell populations. Thus, the higher the deoxynucleoside incorporation rates might occur in populations most susceptible to MTX. However, we saw no relationship between the deoxynucleoside in-corporation rate of peripheral leukemic blasts and the clinical outcome of therapy (Fig. 4) (Fig. 5 D) It is noteworthy that less blockade of UdR incorporation was seen in blasts of nonresponsive patients stud-ied during the 2nd and 3rd infusions, and in vitro their blasts were resistant to MTX as judged by the higher fractional UdR rates seen after half-hour exposure to MTX at 10 moles/liter. This biochemical resistance probably resulted from blasts surviving an MTX infusion, acquiring detectable resistance to MTX during the folinic "rescue" procedure, and then losing this "resistance" less rapidly than the blasts of responsive patients.
Effects of MTX infusions on TdR incorporation. The TdR incorporation rate during the MTX infusion did not seem related to the therapeutic outcome, if one compares the rates/106 blasts. Regardless of how the patients fared, in most cases the TdR incorporation rate at the end of the MTX infusion was elevated above pretreatment values, although the rise perhaps was less marked in the cells of responsive patients (Fig. 7 B) . These changes in TdR rates were unpredictable and were responsible in large measure for the fact that the UdR rates did not coincide with those expected from pretreatment in vitro studies. However, when the product TdR rate/106 blasts times blast count in million/ml of blood (TdR rate/milliliter) was determined before therapy and compared with the postinfusion value, segregation of responsive from nonresponsive patients was partially achieved. Thus, if by the end of the 1st infusion the TdR rate/milliliter remained above pretreatment values, remission was unlikely, while in the group in whom the TdR rate/milliliter decreased below pretreatment values, the majority went on to remission. In all patients, the blast count fell by the end of the infusion, and no difference could be seen in the degree of decline between responsive and nonresponsive patients. Roberts and Hall (61) (68) , hence alterations in enzyme activity with dihydrofolate as substrate would be more relevant to MTX-resistance mechanisms.
Hillcoat, Swett, and Bertino showed DHFR enzyme activity of human cells in culture rose during logarithmic growth (66) . It then declined during the stationary phase, possibly due to proteolysis, but MTX bound to DHFR prevented enzyme decay. Murine L1210 leukemia cells in culture did not show increased enzyme activity during logarithmic growth and MTX failed to produce accumulation of bound enzyme. Furthermore, the mouse cells were more sensitive to MTX than were the human cells. Therefore, an additional difference of major importance between these two cell types in culture or between AGL or AMnL and ALL leukemia in humans may be that in cells showing an enzyme rise, DHFR is turning over faster. This capacity for rapid enzyme synthesis, associated with proliferating cells of a growth fraction which is slowly turning over would be responsible for the relative lack of sensitivity of these cells to MTX therapy. In any case, of all the parameters studied, the patterns observed in the DHFR enzyme activity of blasts during chemotherapy showed the best correlation with clinical outcome. Unfortunately, it was not possible to detect DHFR activity before therapy in many cases, and, hence, the usefulness of this assay in modulating therapy might be quite limited. ' Hillcoat, B. Personal communication.
